Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors
Authors:
- Anastasiya A. GlibkaAGAnastasiya A. Glibka
- Natalya V. MazurinaNMNatalya V. Mazurina
- Ksenia A. SarantsevaKSKsenia A. Sarantseva
- Galina Y. KharkevichGKGalina Y. Kharkevich
- Konstantin K. LaktionovKLKonstantin K. Laktionov
- Ekaterina A. TroshinaETEkaterina A. Troshina
- Galina A. Mel`nIchenkoGMGalina A. Mel`nIchenko
Open Access
- 26 October 2022
- journal article
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 50 (3) , 187-195
Abstract
In the recent years, immune checkpoint inhibitors (ICPI) have been widely used for treatment of many malignant neoplasms. In the Russian Federation, several ICPIs have been approved and actively used, namely anti-CTLA-4 monoclonal antibody (ipilimumab), anti-PD-1 monoclonal antibodies (nivolumab, pembrolizumab, prolgolimab), and anti-PD-L1 monoclonal antibodies (atezolizumab, durvalumab). ICPIs may cause various endocrine immune-mediated adverse events, most commonly thyroid dysfunction and hypophysitis, which are at large associated with anti-tumor therapy with a certain subgroup of these agents. Predictors of endocrine immune-mediated adverse events remain unclear, and their optimal prevention, prediction and treatment have not been yet defined. The review contains the information accumulated in the literature on the mechanisms, biomarkers, specific characteristics of thyroid immune-mediated adverse events and describes the principles of treatment for these thyroid disorders. This information would be useful for practicing oncologists, endocrinologists, internists, family physicians, as well as for any other medical specialties.Keywords
This publication has 26 references indexed in Scilit:
- SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapyEndocrine Connections, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T CellsThyroid®, 2017
- REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGYResearch and Practical Medicine Journal, 2017
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved MechanismsThe Journal of Clinical Endocrinology & Metabolism, 2017
- Risk of Endocrine Adverse Events in Cancer Patients Treated with PD-1 Inhibitors: A Systematic Review and Meta-AnalysisImmunotherapy, 2017
- Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancerAnnals of Oncology, 2016
- Risk of Endocrine Complications in Cancer Patients Treated with Immune Check Point Inhibitors: A Meta-AnalysisFuture Oncology, 2016
- IMMUNE-MEDIATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS THERAPYMalignant tumours, 2016
- Low T3 syndrome in cancer patients in relation to weight loss, intravenous hyperalimentation therapy and age.Endocrinologia Japonica, 1986